Con­gress fires an­oth­er sal­vo at Al­ler­gan’s Mo­hawk deal; AI out­fit rais­es $60M for dis­cov­ery ef­fort

→ Al­ler­gan’s move to try and steer around an IPR re­view of its patents for its $1.5 bil­lion drug Resta­sis by hand­ing them over to an In­di­an tribe for safe­keep­ing was tai­lor made for pub­lic con­tro­ver­sy. And law­mak­ers have proved oblig­ing. Now a bi­par­ti­san group of House mem­bers are set­ting up a probe of the deal, which re­lies on the sov­er­eign im­mu­ni­ty of the Saint Reg­is Mo­hawk tribe to block the IPR. Al­ler­gan CEO Brent Saun­ders wants this to be a fight about the IPR process — what he’s wound up with is a PR bat­tle with al­most no chance of win­ning.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER